MX391037B - Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. - Google Patents
Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.Info
- Publication number
- MX391037B MX391037B MX2017001285A MX2017001285A MX391037B MX 391037 B MX391037 B MX 391037B MX 2017001285 A MX2017001285 A MX 2017001285A MX 2017001285 A MX2017001285 A MX 2017001285A MX 391037 B MX391037 B MX 391037B
- Authority
- MX
- Mexico
- Prior art keywords
- htt
- antibodies
- human
- derived anti
- huntingtin
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14179004 | 2014-07-29 | ||
| PCT/EP2015/067327 WO2016016278A2 (en) | 2014-07-29 | 2015-07-29 | Human-derived anti-huntingtin (htt) antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017001285A MX2017001285A (es) | 2017-04-25 |
| MX391037B true MX391037B (es) | 2025-03-21 |
Family
ID=51225442
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001285A MX391037B (es) | 2014-07-29 | 2015-07-29 | Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. |
| MX2022003706A MX2022003706A (es) | 2014-07-29 | 2017-01-27 | Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. |
| MX2022003704A MX2022003704A (es) | 2014-07-29 | 2017-01-27 | Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003706A MX2022003706A (es) | 2014-07-29 | 2017-01-27 | Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. |
| MX2022003704A MX2022003704A (es) | 2014-07-29 | 2017-01-27 | Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10556946B2 (show.php) |
| EP (2) | EP3174898A2 (show.php) |
| JP (3) | JP2017522886A (show.php) |
| KR (1) | KR102643395B1 (show.php) |
| CN (2) | CN113651887A (show.php) |
| AU (3) | AU2015295441B2 (show.php) |
| CA (1) | CA2954738A1 (show.php) |
| EA (1) | EA201790165A1 (show.php) |
| IL (2) | IL250180A0 (show.php) |
| MX (3) | MX391037B (show.php) |
| WO (1) | WO2016016278A2 (show.php) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| AU2015295441B2 (en) * | 2014-07-29 | 2020-05-14 | Neurimmune Holding Ag | Human-derived anti-huntingtin (HTT) antibodies and uses thereof |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| PL3672631T3 (pl) | 2017-08-22 | 2023-06-26 | Biogen Ma Inc. | Kompozycje farmaceutyczne zawierające przeciwciała przeciw beta-amyloidowi |
| US11851487B2 (en) * | 2019-04-01 | 2023-12-26 | Rensselaer Polytechnic Institute | Methods and systems for detecting peptide aggregates |
| TW202110878A (zh) * | 2019-05-16 | 2021-03-16 | 法商賽諾菲公司 | 在神經系統中表現抗原結合蛋白 |
| AU2020363372A1 (en) | 2019-10-07 | 2022-05-19 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
| US20230067811A1 (en) | 2020-01-24 | 2023-03-02 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
| CN116348487A (zh) | 2020-07-23 | 2023-06-27 | 欧萨尔普罗席纳有限公司 | 抗淀粉样β抗体 |
| CN111909265B (zh) * | 2020-08-25 | 2022-02-11 | 中国人民解放军军事科学院军事医学研究院 | 一种结合破伤风毒素重链c端结构域的人源抗体及应用 |
| AU2022211971A1 (en) | 2021-01-29 | 2023-08-10 | Illimis Therapeutics, Inc. | Fusion molecule having non-inflammatory phagocytosis inducing activity |
| CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
| CN114334076B (zh) * | 2021-12-23 | 2025-03-21 | 华中科技大学 | 一种药食同源中药玉竹的重金属概率风险评估方法及系统 |
| WO2024121347A1 (en) * | 2022-12-07 | 2024-06-13 | Alchemab Therapeutics Ltd | Anti-huntingtin antibodies |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
| ES2178635T3 (es) | 1990-11-09 | 2003-01-01 | Stephen D Gillies | Inmunoconjugados de citoquinas. |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| DE69232604T2 (de) | 1992-11-04 | 2002-11-07 | City Of Hope Duarte | Antikörperkonstrukte |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| ATE236987T1 (de) | 1992-11-13 | 2003-04-15 | Idec Pharma Corp | Konsensus-kozak-sequenzen zur säugetier- exprimierung |
| CA2116280A1 (en) | 1993-03-05 | 1994-09-06 | Marcy E. Macdonald | Huntingtin dna, protein and uses thereof |
| KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| US6255455B1 (en) * | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
| AU737155B2 (en) | 1997-03-14 | 2001-08-09 | Biogen Idec Inc. | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| JP2002512624A (ja) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
| ATE323288T1 (de) | 1997-08-01 | 2006-04-15 | Verfahren zur bestimmung von amyloid-ähnlichen fibrillen oder proteinaggregaten | |
| AU1631700A (en) | 1998-11-23 | 2000-06-13 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| EP1204674A4 (en) * | 1999-07-27 | 2005-06-01 | Abgenix Inc | METHODS AND COMPOUNDS FOR PREVENTING POLYPEPTIDE COLLECTIONS ASSOCIATED WITH NEUROLOGICAL DISORDERS |
| ATE352040T1 (de) | 2000-11-17 | 2007-02-15 | Univ Rochester | In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen |
| CN1494553A (zh) | 2001-01-29 | 2004-05-05 | IDECҩ�﹫˾ | 改变的抗体及其使用方法 |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| CA2438661C (en) * | 2001-02-15 | 2011-05-31 | University Of Chicago | Yeast screens for agents affecting protein folding |
| US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
| US7375194B2 (en) * | 2002-01-28 | 2008-05-20 | California Institute Of Technology | Antibodies that bind to an epitope on the Huntington's disease protein |
| WO2004101787A1 (ja) * | 2003-05-14 | 2004-11-25 | Japan Science And Technology Agency | ハンチンチン遺伝子の発現抑制 |
| EP2502935B1 (en) | 2003-08-22 | 2017-03-29 | Biogen MA Inc. | Improved antibodies having altered effector function and methods for making the same |
| WO2005052002A2 (en) * | 2003-11-20 | 2005-06-09 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
| DK2099826T3 (da) * | 2007-01-05 | 2014-01-20 | Univ Zuerich | Anti-beta-amyloid-antistof og anvendelser deraf |
| US20090304590A1 (en) * | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
| US8022268B2 (en) * | 2007-06-11 | 2011-09-20 | The University Of Zurich | Transgenic animal model for alzheimer's disease |
| AU2009328505B2 (en) | 2008-12-19 | 2014-11-27 | Panima Pharmaceuticals Ag | Human anti-alpha-synuclein autoantibodies |
| LT2627672T (lt) | 2010-10-11 | 2018-12-10 | Biogen International Neuroscience Gmbh | Žmogaus antikūnai prieš tau baltymą |
| CA2818781C (en) | 2010-12-17 | 2019-10-08 | Neurimmune Holding Ag | Human anti-sod1 antibodies |
| US20140044644A1 (en) | 2011-02-21 | 2014-02-13 | University Of Zurich | Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders |
| EP2734234A4 (en) * | 2011-07-20 | 2015-01-28 | Medimmune Ltd | ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF |
| CA2853412C (en) | 2011-10-28 | 2021-05-04 | University Of Zurich | Tdp-43 specific binding molecules |
| EP3950712A1 (en) * | 2013-05-29 | 2022-02-09 | Vybion, Inc. | Single chain intrabodies that alter huntingtin mutant degradation |
| WO2016005545A1 (en) * | 2014-07-10 | 2016-01-14 | Affiris Ag | Substances and methods for the use in prevention and/or treatment in huntington's disease |
| PL3166660T3 (pl) | 2014-07-10 | 2018-07-31 | Affiris Ag | Substancje i sposoby do zastosowania w profilaktyce i/lub leczeniu choroby Huntingtona |
| AU2015295441B2 (en) | 2014-07-29 | 2020-05-14 | Neurimmune Holding Ag | Human-derived anti-huntingtin (HTT) antibodies and uses thereof |
-
2015
- 2015-07-29 AU AU2015295441A patent/AU2015295441B2/en active Active
- 2015-07-29 CN CN202110774704.4A patent/CN113651887A/zh active Pending
- 2015-07-29 EP EP15742303.9A patent/EP3174898A2/en not_active Withdrawn
- 2015-07-29 EP EP24174406.9A patent/EP4406549A3/en active Pending
- 2015-07-29 EA EA201790165A patent/EA201790165A1/ru unknown
- 2015-07-29 CN CN201580040265.7A patent/CN107074937B/zh active Active
- 2015-07-29 MX MX2017001285A patent/MX391037B/es unknown
- 2015-07-29 KR KR1020177005723A patent/KR102643395B1/ko active Active
- 2015-07-29 JP JP2017504353A patent/JP2017522886A/ja active Pending
- 2015-07-29 CA CA2954738A patent/CA2954738A1/en active Pending
- 2015-07-29 US US15/323,784 patent/US10556946B2/en active Active
- 2015-07-29 WO PCT/EP2015/067327 patent/WO2016016278A2/en not_active Ceased
-
2017
- 2017-01-18 IL IL250180A patent/IL250180A0/en unknown
- 2017-01-27 MX MX2022003706A patent/MX2022003706A/es unknown
- 2017-01-27 MX MX2022003704A patent/MX2022003704A/es unknown
-
2020
- 2020-02-07 US US16/784,645 patent/US11401325B2/en active Active
- 2020-06-02 JP JP2020096056A patent/JP7235939B2/ja active Active
- 2020-08-13 AU AU2020217427A patent/AU2020217427B2/en active Active
- 2020-08-16 IL IL276721A patent/IL276721A/en unknown
-
2022
- 2022-06-30 US US17/810,113 patent/US20220332808A1/en not_active Abandoned
-
2023
- 2023-01-19 JP JP2023006564A patent/JP7562168B2/ja active Active
-
2024
- 2024-01-17 AU AU2024200315A patent/AU2024200315A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX391037B (es) | Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. | |
| IL287607A (en) | Preparations, kits and methods for inducing acquired cellular resistance using inducible stress proteins | |
| IL261163B (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| MX375032B (es) | Proteínas de unión y métodos para utilizarlas. | |
| AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| MX391159B (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| IL264454A (en) | Novel compositions, uses and methods for making them | |
| MX391051B (es) | Anticuerpos anti-cd47 y usos de los mismos. | |
| MX2015013202A (es) | Cultivo, produccion, procesamiento y uso de cannabis de especialidad. | |
| PH12017501077A1 (en) | Compositions and methods for antibodies targeting bmp6 | |
| EP3126524A4 (en) | Improved compositions and methods for molecular inversion probe assays | |
| WO2015001013A3 (en) | Human anti-ifn-alpha antibodies | |
| MX378905B (es) | Pestivirus. | |
| CY1120997T1 (el) | Πρωτεϊνες συντηξης uti | |
| BR112016018371A2 (pt) | derivado de indolona substituído com pirrol, método de preparação do mesmo, composição compreendendo o mesmo e uso do mesmo | |
| EA201691493A1 (ru) | Замещенные n-арилпиридиноны | |
| NZ728041A (en) | Substances and methods for the use in prevention and/or treatment in huntington’s disease |